Publications by authors named "A Ben Halima"
Article Synopsis
- Pancreatic acinar cell carcinoma (PACC) is a rare and aggressive tumor with few treatment options beyond surgery, prompting a study of its genomic features.
- The research involved whole-genome and RNA sequencing of samples from 3 metastatic PACC patients, revealing markers of homologous recombination deficiency (HRD) linked to BRCA1/2 and FANCL mutations, which showed positive responses to PARP inhibitors.
- The study also identified significant structural variants and alterations in key pathways, suggesting potential targets for targeted therapies and emphasizing the need for genomic profiling to customize treatment for better outcomes.
Article Synopsis
- * The systematic review included 44 studies and found that females experience higher rates of anxiety and depression, have worse quality of life scores, and are less likely to have certain complications compared to males, who have a higher mortality risk and require more surgeries.
- * Overall, males and females show some differences in mental health and disease management, but no significant variations were noted in hospitalization rates or the overall behavior of the disease.
Article Synopsis
- The study focuses on the effectiveness of adjuvant radiation therapy, specifically intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery (SRS), after subtotal resection of WHO grade II meningiomas due to the limited existing research.
- A retrospective analysis of 39 patients revealed 3-, 5-, and 10-year progression-free survival rates of 81.1%, 61.2%, and 44.6%, respectively, demonstrating overall acceptable control rates.
- No significant differences were found in progression-free survival or radiation necrosis occurrences between the IMRT and SRS groups, suggesting both treatments are similarly effective for managing residual tumors.
Purpose: This phase I study aimed to assess the safety, tolerability, and immunogenicity of the PIKA-adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine in healthy adults aged 18 years and older.
Materials And Methods: This is a phase I, open-label, dose-escalation study at three dose levels (5 µg, 10 µg, and 20 µg) of the PIKA coronavirus disease 2019 (COVID-19) vaccine administered intramuscularly. The three vaccine arms are (A) subjects who have never received any COVID-19 vaccination or have had COVID-19 infection for >6 months prior to enrolment; (B1) subjects whose COVID-19 primary vaccination series was completed with an inactivated COVID-19 vaccine; and (B2) subjects whose primary series was completed with messenger RNA COVID-19 vaccine.